Drugs - Xagena.net - Update in Medicine

Search results for "Trastuzumab"

Kadcyla for advanced HER2-positive breast cancer, approved in EU

Roche has announced that Kadcyla ( Trastuzumab emtansine or T-DM1 ) has been approved by the European Commission for people with previously treated HER2-positive advanced breast cancer. Specifically, ... read article

Perjeta for neoadjuvant breast cancer treatment, FDA approved

The FDA ( Food and Drug Administration ) has granted accelerated approval to Perjeta ( Pertuzumab ) as part of a complete treatment regimen for patients with early stage breast cancer before surgery ( ... read article

Kadcyla for the treatment of adult patients with HER2+, unresectable locally advanced or metastatic breast cancer

The Committee for Medicinal Products for Human Use ( CHMP ) has adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Kadcyla, 100 mg and 160 mg, ... read article

Patients with lung cancer who carry specific HER2 mutations may benefit from certain anti-HER2 drugs

New results from a retrospective study suggest that anti-HER2 treatments, like the widely used breast cancer agent Trastuzumab ( Herceptin ), have anti-cancer effects in a small subset of patients wit ... read article

Hormone positive and HER2-positive advanced breast cancer: Tykerb in combination with Femara

The FDA ( Food and Drug Administration ) approved Tykerb ( Lapatinib ) in combination with Femara ( Letrozole ) to treat hormone positive and HER2-positive advanced breast cancer in postmenopausal wom ... read article

Women with HER2+ breast cancer: Pertuzumab and Trastuzumab combination improves efficacy

The phase II study results of the NeoSphere neoadjuvant trial has shown that the combination of Trastuzumab ( Herceptin ) and Pertuzumab ( Omnitarg ) had superior antitumor activity in women with ear ... read article

Aggressive inflammatory breast cancer: treatment with Lapatinib

Lapatinib ( Tykerb ) could be used to treat inflammatory breast cancer, an aggressive from of the disease which represents up to one tenth of malignant breast cancer cases. The findings of this phase ... read article

Metastatic HER2+ breast cancer: triple drug combination is promising option

Combining two chemotherapy drugs with Trastuzumab ( Herceptin ) to treat women who have metastatic HER2+ breast cancer may offer physicians another choice in their treatment options. Researchers at ... read article

Breast cancer survival improves using Herceptin with chemotherapy

Using Herceptin ( Trastuzumab ) with chemotherapy, instead of after, clearly improves treatment of women with HER2+ breast cancer, and should be the new standard of care. Patients using Herceptin ... read article

Breast cancer: oligohydramnios associated with Herceptin

Hoffmann-La Roche, in consultation with Health Canada, has informed HealthCare Professionals of important new safety information regarding the use of Herceptin ( Trastuzumab ) during pregnancy. Her ... read article

Inflammatory breast cancer: Lapatinib could be used to treat patients with aggressive form

Lapatinib ( Tykerb ) could be used to treat inflammatory breast cancer, an aggressive from of the disease which represents up to one tenth of malignant breast cancer cases. Inflammatory breast can ... read article

Metastatic HER2+ breast cancer: a combination of Capecitabine, Vinorelbine, and Trastuzumab is promising option

Cancer: new biomarkers can predict response to treatments

Genetic variations ensure that no two people are exactly alike, nor are their cancers. Researchers now have the tools and the knowledge to predict how individuals will respond to cancer therapy, enabl ... read article

Increased risk of recurrence for patients with early stage, HER2-positive breast cancer

Early-stage breast cancer patients with HER2 positive tumors one centimeter or smaller are at significant risk of recurrence of their disease, compared to those with early-stage disease who do not exp ... read article

Breast cancer: management and prognosis

As therapies for breast cancer continue to emerge, the issues of how to best monitor success and gauge prognosis remain important questions.The following abstracts have been presented at the CTRC-AACR ... read article

Focus

New indication for Eylea in EU: treatment of visual impairment due to macular edema secondary to central retinal vein occlusion

Bayer HealthCare has announced that Eylea ( Aflibercept solution for injection ) has been approved by the European Commission ( EC ) for the treatment of visual impairment due to macular edema seconda ... read article

Ibrutinib shows efficacy as treatment for chronic lymphocytic leukemia and mantle cell lymphoma

Two clinical studies published in the New England Journal of Medicine ( NEJM ) suggest that the novel agent Ibrutinib shows real potential as a safe, effective, targeted treatment for adults with chro ... read article

Olmesartan Medoxomil can cause sprue-like enteropathy

FDA ( Food and Drug Administration ) has warned that the blood pressure drug Olmesartan Medoxomil ( marketed as Benicar, Benicar HCT, Azor, Tribenzor, and generics ) can cause intestinal problems know ... read article

Barrett's esophagus: Acetylsalicylic acid may fight cancer by slowing DNA damage

Aspirin ( Acetylsalicylic acid ) is known to lower risk for some cancers, and a new study led by a UC San Francisco researcher, Carlo Maley, points to a possible explanation, with the discovery that A ... read article

Metastatic or unresectable melanoma: FDA approves Tafinlar and Mekinist

The Food and Drug Administration ( FDA ) has approved two new drugs, Tafinlar ( Dabrafenib ) and Mekinist ( Trametinib ), for patients with advanced ( metastatic ) or unresectable melanoma, the most d ... read article

Giant cell tumor of the bone: FDA approves Xgeva

The Food and Drug Administration ( FDA ) has expanded the use of Xgeva ( Denosumab ) to treat adults and some adolescents with giant cell tumor of the bone ( GCTB ), a rare and usually non-cancerous t ... read article

Riociguat has demonstrated significant and sustained improvements in 6MWD and WHO functional class in patients with pulmonary arterial hypertension

Data from the interim analysis of the on-going PATENT-2 trial with Riociguat, the open-label long-term extension of the pivotal Phase III study PATENT-1, were presented at the American Thoracic Societ ... read article

Canagliflozin, a SGLT2 inhibitor, for the treatment of adults with type 2 diabetes

Janssen Pharmaceuticals has announced the FDA ( Food and Drug Administration ) has approved Invokana ( Canagliflozin ) for the treatment of adults with type 2 diabetes. Invokana is the first in a new ... read article